A combination of anti-PD-L1 (durvalumab) and anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (anti-CTLA-4; tremelimumab) antibodies is additional first-line treatment for advanced HCC [12,16]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.